Search Results

At 2Logical, we systematically assess the size and distribution of Oncology in Portugal, transforming fragmented data into structured and comparable insights. In this particular Lung Cancer analysis, the data highlights that the care burden is not evenly spread. There’s a limited number of reference centers that manage the vast majority of cases. Top 3 National Accounts by Prevalence LUNG CANCER These Top 3 accounts manage 21% of all active patients nationwide. Top 3 National Accounts by Incidence LUNG CANCER These Top 3 accounts manage 16% of all active patients nationwide. In parallel, the regional analysis reveals marked territorial differences, with certain regions concentrating a disproportionate share of the national volume. Territorial Differences in Volume LUNG CANCER In Oncology, this type of analysis is particularly valuable: Understanding the true size of a market and how it’s distributed is essential for making decisions grounded in local clinical reality. Where is the Industry Investing? TOP ONCOLOGY AREAS BY REPORTED INVESTMENT Total investment fell in 2025 , with Oncology’s share dropping from 12% to 10%. Despite this decline, spending shifted toward Healthcare Professionals (HCPs). While entities received 58% of funds in 2024, the distribution became more balanced in 2025 as HCP investment rose to 47%. Recalled F2F Interactions Increased by 4,699 in 2025, Compared to 2024 The increase in F2F interactions in 2025 further confirms a strategic reinforcement of proximity with oncologists, positioning F2F as a key channel for high-value engagement in this specialty. In Oncology, content effectiveness clearly varies by channel. “The right channel, for the right content” 🎗️📊 When data is structured, consistent and clinically grounded, it changes how oncology is understood. Reliable insights start with data quality, and that’s where meaningful analysis begin to create the conditions for more a informed, timely and patient-centred care. On this World Cancer Day, we highlight the critical role of high-quality data in shaping a clearer understanding of the oncology landscape.

In Portugal, 1 in 2 patients followed across major medical specialties live with overweight or obesity. This clinical reality helps explain the growing investment, scientific activity and healthcare professional engagement observed in obesity today. Industry investment continues to grow Leading companies are intensifying their presence, signaling long-term strategic commitment to obesity management. Scientific exchange remains a central driver of knowledge dissemination and clinical alignment. Engagement & Omnichannel Dynamics Healthcare professionals are responding positively to evolving engagement approaches. CHANNEL SPLIT Obesity - FY 2025 Brand visibility closely follows investment and engagement intensity. Coverage & Frequency Leaders combine high coverage with sustained interaction frequency, while other players maintain selective engagement strategies. Coverage & Frequency GP - Obesity MAT Q4 2025 Coverage & Frequency Endo - Obesity MAT Q4 2025

On the occasion of World Multiple Sclerosis Day on May 30, 2Logical interviewed neurologists from Italy, Portugal, and Spain, with the aim of providing an updated and multidisciplinary overview of the clinical, therapeutic, and organizational evolution in the management of a disease that affects millions of people worldwide. From early diagnosis to artificial intelligence, addressing the challenge of progressive forms, this article provides an integrated view of Multiple Sclerosis (MS), enriched by the contributions of experts such as Dr. Orofino , a medical director of Neurology at the University Polyclinic of Cagliari.    More Tools, Greater Complexity All specialists agree: in the last five years, the management of MS has made significant progress. Therapeutic options have increased, and the personalization of approaches has strengthened. “ Management is now heavily oriented towards immunomodulation, much more than it was in the past ,” emphasizes Dr. Orofino , who also highlights the growing use of high-efficacy therapies (HET) in the early stages of the disease. From Portugal, there is an observed acceleration in the initiation of treatments after diagnosis, while Spain shows a commitment towards increasingly patient-centered medicine. At the European level, there is growing attention to progression, brain atrophy, and therapeutic response  as new frontiers in clinical monitoring.   Progressive Forms and the Need for Biomarkers Despite the successes, neurologists emphasize an urgent need: effective therapies for the progressive forms  of MS, particularly Primary Progressive MS (PPMS) . Current therapeutic approaches still show significant limitations in slowing the progression of disability. “We still lack integrated treatments to combat the progression of disability,”  a concern that Dr. Orofino  shares, also highlighting the lack of a widespread support network, not only in medical terms but also psychological, care, and rehabilitation."   New Patient Profiles and Unmet Needs The clinical profile of patients at diagnosis  is changing. Neurologists report greater variability in terms of age, symptoms, and clinical form. Some Italian specialists have observed increased immune reactivity, while in Portugal, there is a reported increase in prevalence and greater aggressiveness from the onset. Among the unmet needs  are: Treatments for PPMS and SPMS Progression control independent of relapses (PIRA) Better management of invisible symptoms (fatigue, pain, cognitive decline) Access to multidisciplinary teams and rehabilitation programs Personalization of therapies, supported by biomarkers   Quality of Life and Psychosocial Impact When asked which aspects of MS are undervalued in research or daily clinical practice, neurologists indicated several areas. The etiopathogenesis of the disease remains a central concern for some, as do environmental factors. Others highlighted “quality of life and patient independence from caregivers,” “cognitive and psychiatric impact,” and “fatigue and changes in the emotional sphere.” The ability to predict relapses was also mentioned.   The Ideal Therapy and Vision for the Future In the search for the ideal therapy, neurologists hope for a treatment with "high efficacy, high safety, and practicality (oral or low frequency)." They expect a therapy that also has "high adherence and tolerability," and is capable of "repairing and neuroprotecting." The ability to "prevent progression" is a shared desire. Dr. Orofino believes the ideal therapy should be: effective, easy to use, and well-tolerated; preferably taken at home. The vision for the next 10 years is one of hope but also realism. There is an expectation for "new therapies and new knowledge on etiology," "more patients with MS but with less disability," and "better control of the disease and its progression." The chronicization of the disease with a good quality of life represents a goal, as does the development of “more effective therapies for progressive forms and reparative therapies.” For many Italian doctors, personalized medicine will be the key to the future.   The Role of Artificial Intelligence In the context of MS, Artificial Intelligence is seen as a promising tool for the future management of the disease. For Dr. Orofino , artificial intelligence will assist “in the choice of treatments and in predicting long-term effects,” improving the accuracy and timeliness of clinical decisions.   Research Priorities If they could guide new lines of research, specialists would focus on: Etiology and environmental factors Therapies for progressive forms and early biomarkers Neuroprotection and remyelination Pathophysiology of MS Dr. Orofino would direct his research towards techniques for delivering drugs to specific sites in the nervous system.     A Message of Hope and Collaboration The journey of patients with MS is complex and individual, but progress in understanding and treating the disease is remarkable. The perspectives shared by neurologists demonstrate a continuous commitment to improving the quality of life for patients and fuel hope for a future in which MS will be managed more effectively and personalized. Collaboration among researchers, clinicians, the pharmaceutical industry, and, above all, patients and their associations will continue to be the driving force for a future where Multiple Sclerosis can be managed more effectively and personalized.    Acknowledgments 2Logical sincerely wishes to thank the neurologists who generously shared their knowledge and strategic insights. A special thanks to Dr. Orofino  for his contribution. Also participating were: Dr. Roberto Bergamaschi (Italy) Dr. Franca Bilora (Italy) Dr. Iodice (Italy) Dr. Menichetti (Italy) Dr. Paolo Bellantonio (Italy) In addition to the names listed above, other doctors experienced in the management of Multiple Sclerosis participated, who, while preferring not to be identified, provided valuable contributions to the content of this article. Our heartfelt thanks go to all of them.

In order to stay competitive within the pharma and healthcare industries, companies must constantly fine-tune their marketing strategies in order to stay ahead. That’s why we are excited to announce the migration of our e-mail marketing service to a new AI-powered marketing automation system. Why Marketing Automation? Automation is more than just efficiency: it’s about creating consistent and meaningful interactions with your target audience. By automating repetitive tasks and optimizing campaign management, our clients save valuable time and resources. Imagine having a marketing assistant that never sleeps, working tirelessly around the clock to keep your campaigns running smoothly and is constantly learning about your target’s ever-changing preferences. Our AI-powered tools allow us to personalize and automate marketing actions, ensuring that communication remains consistent across all channels. In turn, this gives our clients more time to focus on the strategic planning and creative fronts, while our tools take care of the details. Personalized Messaging at the Perfect Time One of the key benefits of our new system is the ability to tailor messages to the unique preferences of each recipient. Powered by data from 2Logical’s Customer Engagement study , our system can craft personalized subjects for each individual recipient and send them at an optimal date and time, according to their previous interactions. This personalized approach not only enhances the experience of each recipient but also significantly boosts open and click-through rates. The result? More effective marketing campaigns that drive engagement and conversions. Seamless Integration Across Multiple Channels Our tools also allow for the possibility of integrating each campaign across multiple platforms such as WhatsApp, SMS and call center. This ensures that no matter where your customers are, they receive your messages in a consistent and cohesive manner, enhancing their overall experience with your brand. Enhanced Analytics for Data-Driven Decisions Understanding how your campaign performs is essential for making informed adjustments and finding room for improvement. That’s why we’ve enhanced our analytics capabilities by providing deeper insights into each campaign’s metrics. This helps our clients track their performance at a micro level and more easily identify what works and what doesn’t. Why Choose 2Logical’s AI-Powered Marketing Automation? With 2Logical as your marketing partner, you gain access to a powerful toolset designed to enhance your marketing efforts and deliver measurable results. Whether you’re looking to save time, personalize customer interactions, or looking for an easy way to integrate your marketing channels, our Marketing Automation services provide the flexibility and efficiency needed to meet your goals. Get in touch with us today to learn how our solutions can transform your business and take your marketing to new heights. Gabriel Crespo - Tech & Data Science Manager

How do we ensure that scientific progress is not just achieved, but also understood, trusted and applied? We are living in an era of unprecedented access to information, yet we are equally confronted with unprecedented levels of misinformation. The COVID-19 pandemic accelerated scientific breakthroughs at an unmatched pace, it also highlighted the growing challenge of effectively communicating these advancements. At the same time, the rapid evolution of digital platforms, the rise of AI-generated content and the increasing influence of social media have made it difficult to distinguish facts from noise, especially in the healthcare space. That’s where Medical Writing  becomes an essential key to transform complex data into meaningful, credible content for professionals, patients and the general public. At 2Logical, we’ve long been committed to turning data into insights. Now, with our Medical Writing service, we go one step further — shaping those insights into scientifically rigorous, strategically crafted materials. From scientific articles  to infographics , congress posters  and social media scripts , this article explores how Medical Writing plays a pivotal role across the spectrum of healthcare communication and why it matters now more than ever. Why Medical Writing Matters Now In today’s healthcare landscape, clear and accurate communication  is no longer just a best practice, it’s a necessity. The post-pandemic world, shaped by an explosion of health data, rapid technological advancement and an increasingly digital-first public, has shown us that data alone is not enough. With growing investment in clinical research, the way information is communicated , from word choice and structure to how content is adapted for different levels of health literacy, directly impacts how medical advances are perceived, trusted and ultimately adopted. Scientific data, health trends and real-world data are powerful, but only when translated into messages that resonate with each stakeholder , whether it’s an oncologist learning about a new product or a patient trying to understand their diagnosis. From supporting a product launch, increasing the visibility of clinical trial results, or building awareness around a therapeutic area, well-crafted communication plays a fundamental role in ensuring that the right message reaches the right audience, at the right time. Flexible Communication Solutions Tailored to Specific Needs Our Medical Writing  services were built with flexibility and scientific excellence at its core. Our team has years of experience delivering healthcare insights, know how to turn data into strategy — and now, also into scientific materials, training tools  and health-literacy content. By integrating seamlessly with our existing research and consulting solutions, we can support our clients at every stage: from data generation and insights to the creation of high-quality communication materials tailored to their specific needs. We offer a wide range of flexible and customized formats, including: Scientific content:  Abstracts, white papers, peer-reviewed manuscripts/articles, posters, presentations, etc. Education and training:  Infographics, newsletters, articles or trials summaries, etc. Health literacy:  Flyers/brochures, newsletters, social media contents, scripts for videos or podcasts, etc. Fighting Misinformation with Clarity and Purpose At a time when misinformation can spread faster than facts, communicating science clearly, responsibly and meaningfully is an important tool. Whether it’s supporting evidence-based decisions, improving health literacy, or helping innovations reach those who need them most  — Medical Writing plays a critical role in shaping the way information is shared and understood. When developed with scientific rigor, strategic insight  and audience-centered thinking , content becomes more than a translation of data, it becomes a driver of clinical confidence, innovation uptake and better health outcomes. Clear communication builds trust, stimulates action, and supports progress. That’s why we believe Medical Writing matters, now more than ever. Let’s work together to ensure that every insight is communicated with the clarity it deserves. Carolina Gonçalves - Medical Writing Product Manager

We are living through a time of profound transformation in the way healthcare is designed and delivered. Therapeutic innovations follow one another, services are becoming more digital and organizational models are constantly being reconfigured. However, parallel with this progress, a fundamental question remains: do we truly understand what patients experience, at every moment of their journey, including their journey through the healthcare system? The essence of the patient journey goes far beyond diagnoses and treatments. It is made up of decisions, doubts, expectations and obstacles - many of which remain invisible to traditional metrics. Understanding it is more than an exercise in empathy: it is an essential and strategic tool for improving results and guiding actions that are more aligned with the real needs of patients and the entire surrounding circuit.   Why talk about Patient Journey now? In a context marked by the fragmentation of care, increasing pressure on resources and the complexity of clinical trajectories, it is essential to adopt a more integrated perspective on the health system. Building the Patient Journey allows us to: Understand the patient in all dimensions of their life (360º assessment) - capturing a realistic and personal view of their experience and the experience of those around them; Characterize patients' real journeys, mapping the different moments of interaction with the health system, from the first signs of illness to post-treatment follow-up; Identify relevant variations between different socio-demographic contexts and/or organizational models (e.g. public vs. private care); Understand the times between the various stages of the journey; Identify points of inefficiency and discontinuity - processes where information can be lost, delays in access, duplication of tests, failures in coordination between primary, hospital and community care, etc; Analyze behavioral and decision-making determinants, including risk perceptions, demand patterns, health literacy deficits and factors that condition therapeutic adherence; Evaluate the adequacy of communication and interventions, cross-referencing real needs with the responses offered by the various stakeholders; To generate actionable knowledge for decision-making, guiding solutions that are more patient-centered and more effective from a clinical, economic and operational point of view.   But how do you build a Patient Journey in practice? Building a Patient Journey requires methodologies that integrate conventional approaches such as interviews, focus groups and questionnaires, often combined with more differentiated methods - such as immersive sessions, ethnographic journeys, digital diaries or co-creation / design thinking workshops with patients and/or healthcare professionals. Combining these approaches makes it possible to build an integrated view of the patient by identifying critical points and barriers at the various stages of the journey, signalling opportunities for improvement that translate into practical recommendations to optimize experiences and results. Understanding to transform Studying the Patient Journey is not just an analytical tool - it's a starting point for improving the way care is designed, delivered and communicated. It's about seeing the healthcare system in a more integrated, clearer and more strategic way. At 2Logical, we help turn complexity into clarity and data into action, with the goal of supporting interventions that are more effective and more in line with lived realities.   Francisca Caldeira - Business Insights Qualitative Executive @2Logical

Apesar dos progressos, as doenças cardiovasculares continuam a ser das principais causas de mortalidade em Portugal. As doenças do aparelho circulatório  foram responsáveis por mais de 32.000 óbitos em Portugal — cerca de 26% de todos os óbitos . As doenças cardiovasculares  permanecem como uma das causas de maior mortalidade no país. No estudo RADICAL , quase 9 em cada 10 portugueses  possuem pelo menos um fator de risco cardiovascular . 37% da população  apresentou 3 ou mais fatores de risco  combinados: Prevalências estimadas Na população adulta De acordo com o estudo associado ao INSEF, 37% da população portuguesa entre os 40 e os 69 anos  apresenta um risco elevado de desenvolver doença cardiovascular  nos próximos 10 anos , e 6%  têm risco muito elevado . No total, somando ambos os grupos, 43%  das pessoas nesta faixa etária estão em risco elevado ou muito elevado . Apesar das melhorias recentes em alguns indicadores e da evolução favorável da mortalidade por doenças cardiovasculares , Portugal continua a enfrentar disparidades regionais significativas , tanto no controlo dos fatores de risco  como na mortalidade entre regiões do país. As doenças cardiovasculares  mantêm-se entre as principais causas de morte em Portugal . Os fatores de risco são altamente prevalentes: hipertensão , colesterol , obesidade e sedentarismo . Uma percentagem elevada da população (+40%) está em risco elevado a 10 anos . A discrepância entre regiões  e o controlo dos fatores de risco  indicam oportunidades claras para intervenções preventivas. Reforçar campanhas de prevenção  primária, a  deteção precoce  e a  gestão contínua  dos fatores de risco é fundamental para reduzir o impacto das doenças cardiovasculares . 👉 Neste Dia Mundial do Coração, deixamos um apelo: reforçar a prevenção, apostar na deteção precoce e na gestão contínua dos fatores de risco.

O futuro não é apenas digital ou presencial - é a combinação inteligente de ambos. O mercado farmacêutico em Portugal mantém um volume estável de interações  (cerca de 1,8 milhões por trimestre), mas a sua composição está a mudar.  Evolução Global do Mercado A visita pessoal (F2F)  perdeu peso no mix de comunicação. O digital , por outro lado, ganhou espaço. Apesar da transição digital, os canais pessoais continuam centrais.  A visita pessoal  mantém-se dominante, mas em queda lenta.  O email ganha cada vez mais relevância como canal de reforço e fidelização , enquanto a visita remota cresce de forma discreta mas estratégica. Evolução dos Canais Pessoais e Digitais O Email está em forte ascensão, tendo crescido trimestre após trimestre e assumindo-se como o principal canal digital. A Visita Remota  regista um crescimento discreto mas consistente, especialmente útil em contextos de difícil acesso ou com especialidades mais digitais. Digital vs Omnichannel Especialidades  Cada especialidade apresenta um comportamento distinto.  Algumas mostram clara abertura ao digital, outras mantêm-se tradicionais no presencial. Outras ainda já estão num ponto de equilíbrio omnichannel. Medicina Geral e Familiar Diferenças Regionais A Medicina Geral e Familiar (MGF), a especialidade com maior volume , evidencia diferenças regionais marcadas.  Lisboa e Vale do Tejo destacam-se pelo peso do digital, o Norte continua quase exclusivamente presencial e o Centro apresenta maior utilização dos canais “Outros”.   Norte Predominância absoluta do presencial (acima de 70%). Centro Maior peso em canais Outros, além de equilíbrio relativo. Lisboa e Vale do Tejo Forte abertura digital (~ 50%). Empresas com a Abordagem Mais Equilibrada As empresas que melhor equilibram digital e presencial são também as que apresentam maior diversificação de canais.  Líderes de mercado exploram mais de 8 canais distintos , garantindo cobertura em múltiplas especialidades e perfis de HCP. Empresas com maior equilíbrio de canais Estas empresas conseguem distribuir interações de forma balanceada entre F2F e digital. Avaliação Global Estas empresas têm, em média, uma avaliação superior à média do mercado (NPS=42) , confirmando que estratégias omnichannel são não só mais eficazes em alcance, mas também mais valorizadas pelos HCPs. O mercado está em plena transformação omnichannel . O digital cresce, mas o F2F continua essencial.  O email e a visita remota  são canais digitais que complementam o presencial, criando mais impacto e eficiência. As empresas líderes já provaram que o equilíbrio entre canais, em vez da aposta exclusiva em presencial ou digital, é o caminho que garante maior alcance, engagement e retorno. Omnichannel não é uma opção: é uma necessidade. O futuro não é apenas digital ou presencial, trata-se da combinação inteligente de ambos. As empresas capazes de alinhar canal, conteúdo e contexto conquistam cada mais relevância junto dos HCPs e maximizam o retorno dos seus investimentos.

🎗️🩷 Outubro termina, mas o compromisso com quem vive com Cancro da Mama continua. No âmbito da iniciativa "No cancro, não há perguntas tontas, todas as dúvidas são importantes" , a 2Logical, em colaboração com associações de doentes e com o Grupo Patients Advocacy da Sociedade Portuguesa de Oncologia , desenvolveu um estudo junto de pessoas com Cancro da Mama em Portugal. O objetivo? Perceber que dúvidas os doentes têm, mas nem sempre exprimem, e em que momentos estas surgem com maior frequência. Este estudo procura: Compreender as necessidades de informação ao longo da jornada da doente; Identificar os momentos onde surgem mais dúvidas; Entender por que razão certas questões não são colocadas ao médico; Melhorar a comunicação entre doentes e profissionais de saúde. Cerca de ¼ das pessoas diagnosticadas com Cancro da Mama não sabem o subtipo de cancro que têm/tiveram. 39,1% das pessoas diagnosticadas com Cancro da Mama foram diagnosticadas nos estadios precoces (0 a II). Cerca de metade das pessoas com diagnóstico de Cancro de Mama já receberam o mesmo há mais de 2 anos. Mais de 72% das pessoas diagnosticadas com Cancro da Mama dizem que conseguem expressar sempre ou frequentemente todas as suas dúvidas com o médico, mas há cerca de 17% que dizem que o fazem apenas ocasionalmente ou raramente. A vida sexual, auto-imagem e trabalho são os aspetos mais afetados pelos tratamentos.

Is your brand actually reaching its audience? Or are you being left out of the conversation? For years, mastering SEO (Search Engine Optimization) was essential. All that was needed was to optimize keywords, build backlinks and ensure that navigation on the site was quick and intuitive. Nowadays, it's not that simple. With the rise of Artificial Intelligence and conversational search, we find ourselves in the age of AEO - Answer Engine Optimization . And to keep up with this change, it's essential to talk about Real-Time Digital Profiles . What changed recently? For the pharmaceutical and healthcare industry, this change is having a direct impact on the way companies relate with doctors, pharmacists and even patients themselves. The search for clear and reliable answers (for example, about new treatments or OTC drugs) is now increasingly done using AI interfaces or voice searches. To be absent when these answers are given means losing visibility at critical decision-making moments. Nowadays, users are no longer just looking for keywords. They are asking questions and expecting straightforward, quick and personalized answers , often through voice searches or AI interfaces (such as ChatGPT or Google's Gemini). And the AI delivers. Instead of presenting a list of links, which is what search engines have done until now, they seek to give the best possible answer  directly on the results page. AEO ( Answer Engine Optimization ): what is it and why it matters? AEO is the natural evolution of SEO: the focus is no longer on climbing the rankings, but rather on ensuring that the information presented is relevant, reliable and directly useful in answering users' questions.   And how is this achieved?   Creating clear, concise and factual content. Directly answering the most common questions from the audience in question. Using structured data (e.g. schema.org ). Schema.org  is a markup language created by companies such as Google, Microsoft and Yahoo that allows you to add extra “context” to the content of a website. Instead of a simple paragraph of text, this markup helps search engines understand exactly what you're talking about. Using natural, conversational language - like you're interacting in a conversation. A practical illustration of this is, for example, when a pharmaceutical company releases data from a new study or prescription guidelines. A simple landing page is not enough. It is essential that the content is structured so that an AI can quickly extract and return the answer to the question: “Can this drug be used in patients with type 2 diabetes and kidney failure?”   The role of Real-Time Digital Profiles To successfully achieve all of this, it's first important to know your target audience well and in real time. This is where Real-Time Digital Profiles  are useful: dynamic, constantly updated representations that aggregate data from various sources (websites, social networks, CRM, apps, emailings, etc.). For brands, these profiles enable them to: Anticipate customer needs. Personalize experiences and content. Create accurate responses - something highly valued by algorithms when forming responses. Make quick and more informed decisions. Through 2Logical's HCP segmentation, profiling and digital scoring services, our clients are able to build these Profiles in Real Time based on real data. Channel preferences, interaction history, specialty and even prior campaign behavior are just a few examples of the capabilities at their disposal. This allows the responses generated by the AIs to be even more relevant and tailored to the caller. But this doesn't mean the end of SEO. It's a transformation. If you think SEO is going to disappear, think again. It's no longer enough on its own when it comes to getting visibility online. AEO complements it and expands the rationale behind SEO, adapting it to a reality where users want to see answers, not just links.   Classic SEO Modern AEO Goal Be found on Google Be the straightforward answer that AI provides Content Focused on technical keywords Focused on quick answers about therapeutic use, studies and guidelines Optimization For search engines For response engines, chatbots and voice Success Metrics Organic traffic AI response mentions, direct visibility   And so, what now? If you're looking to prepare your brand for this new reality, here are some practical tips: Invest in content that answers questions  FAQs, quick guides, educational and “to the point” content. Use structured data Make life easier for algorithms by marking up your content with Schema.org . Continuously monitor and update your users' data Adjust your communication and anticipate your audience's needs more accurately. Invest in AI and automation For content analysis, personalization and delivery. Focus on experience and conveying trust Focus on experience and conveying trust   We are entering a new era of digital marketing - more conversational, more personalized and more immediate. Ignoring AEO  and real-time digital profiles  risks losing relevance in a world where being seen means  being useful at the right time. Today we are going through a new era of digital marketing - more conversational, personalized and immediate. At 2Logical we have been supporting companies in redefining their digital presence and creating content prepared for this new paradigm. José Domingues - Marketing & Innovation Manager @2Logical

O Cancro da Mama está a aumentar entre mulheres jovens. Dados recentes de 2024 indicam que a incidência na faixa etária dos 20 aos 49 anos subiu significativamente nos últimos anos (2017-2019), chegando aos 75 casos por 100.000 mulheres, em comparação com cerca de 65 casos registados nas décadas anteriores (2000-2016). Este crescimento sublinha a necessidade urgente de intensificar a pesquisa e a inovação na área do Cancro da Mama. ​ Porque o Cancro da Mama não espera por Outubro. Neste webinar, a Dra. Margarida Brito , médica oncologista no IPO de Lisboa, partilhou insights valiosos sobre: ​ Dados epidemiológicos:  Incidência e prevalência em Portugal vs. contexto mundial. Standard of Care (SoC): Tratamentos disponíveis por setting clínico. Inovações emergentes:   O que o futuro reserva no tratamento do Cancro da Mama.    Assista à sessão na íntegra e mantenha-se atualizado sobre os avanços no tratamento do Cancro da Mama.